세계의 간질환 치료 시장 리포트(2023년)

“Liver Diseases Therapeutics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver diseases therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The liver diseases therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer

• 2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids

• 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users

• Companies Mentioned: Astellas Pharma Inc.; Bristol-Myers Squibb Company; F Hoffmann-La Roche AG; Merck & Co Inc.; Novartis AG

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery Format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the liver diseases therapeutics market are: Astellas Pharma Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, GlaxoSmithKline Plc, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, Abbvie Inc., The Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., and AstraZeneca plc.

The global liver diseases therapeutics market is expected to grow from $12.10 billion in 2022 to $13.09 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The liver diseases therapeutics market is expected to grow to $17.41 billion in 2027 at a CAGR of 7.4%.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Liver disease therapeutics refers to the treatment of numerous types of liver illnesses, diseases brought on by viruses including hepatitis A, B, and C. These diseases are mainly caused by consuming more alcohol.

North Ameria was the largest region in the liver diseases therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main disease types of liver disease therapeutics are hepatitis, non-alcoholic fatty liver disease, alcohol-induced, and liver cancer. Hepatitis refers to an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems, some of which can be fatal. The treatment is antiviral, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. The end-users included hospitals, ambulatory surgery centers, and other end-users.

The rising prevalence of liver diseases is expected to propel the growth of the liver disease therapeutics market going forward. Liver disease refers to any condition that has been affecting the liver. Liver disease therapeutics help in treating liver diseases through various treatments. For instance, in 2020, according to The Centers for Disease Control and Prevention (CDC), the number of deaths from alcoholic liver disease was 29,505 in the United States. Therefore, the rising prevalence of liver diseases drives the growth of the liver disease therapeutics market.

Strategic partnerships are a key trend gaining popularity in the liver disease therapeutics market. Major companies operating in the liver diseases therapeutics market are undergoing collaborations to strengthen their position in the liver diseases therapeutics market. For instance, in January 2022, Aligos Therapeutics Inc., a US-based clinical-stage biopharmaceutical company collaborated with Merck & Co, a US-based company operating in liver disease therapeutics. This collaboration is to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis. Further, in January 2021, Novartis, a Switzerland-based company operating in liver disease therapeutics collaborated with Alnylam, a US-based biopharmaceutical company. This collaboration aims to develop liver-targeted therapy as a potential alternative to transplantation for patients experiencing liver failure.

In September 2022, GENFIT, a France-based biopharmaceutical company acquired Versantis for an undisclosed amount. This acquisition of Versantis' expertise with GENFIT's know-how in conducting complex development programs in liver diseases, strengthens and accelerates research and development and significantly expands GENFIT's pipeline. Versantis is a Switzerland-based company operating in liver disease therapeutics.

The countries covered in the liver diseases therapeutics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Liver Diseases Therapeutics Market Characteristics

3. Liver Diseases Therapeutics Market Trends And Strategies

4. Liver Diseases Therapeutics Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Liver Diseases Therapeutics Market
• 4.2. Ukraine-Russia War Impact On Liver Diseases Therapeutics Market
• 4.3. Impact Of High Inflation On Liver Diseases Therapeutics Market

5. Liver Diseases Therapeutics Market Size And Growth

• 5.1. Global Liver Diseases Therapeutics Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Liver Diseases Therapeutics Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Liver Diseases Therapeutics Market Segmentation

• 6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer
• 6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids
• 6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospitals
• Ambulatory Surgery Centers
• Other End Users

7. Liver Diseases Therapeutics Market Regional And Country Analysis

• 7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Liver Diseases Therapeutics Market

• 8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Liver Diseases Therapeutics Market

• 9.1. China Liver Diseases Therapeutics Market Overview
• 9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Liver Diseases Therapeutics Market

• 10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Liver Diseases Therapeutics Market

• 11.1. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Liver Diseases Therapeutics Market

• 12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Liver Diseases Therapeutics Market

• 13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Liver Diseases Therapeutics Market

• 14.1. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Liver Diseases Therapeutics Market

• 15.1. Western Europe Liver Diseases Therapeutics Market Overview
• 15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Liver Diseases Therapeutics Market

• 16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Liver Diseases Therapeutics Market

• 17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Liver Diseases Therapeutics Market

• 18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Liver Diseases Therapeutics Market

• 19.1. Eastern Europe Liver Diseases Therapeutics Market Overview
• 19.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Liver Diseases Therapeutics Market

• 20.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Liver Diseases Therapeutics Market

• 21.1. North America Liver Diseases Therapeutics Market Overview
• 21.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Liver Diseases Therapeutics Market

• 22.1. USA Liver Diseases Therapeutics Market Overview
• 22.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Liver Diseases Therapeutics Market

• 23.1. South America Liver Diseases Therapeutics Market Overview
• 23.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Liver Diseases Therapeutics Market

• 24.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Liver Diseases Therapeutics Market

• 25.1. Middle East Liver Diseases Therapeutics Market Overview
• 25.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Liver Diseases Therapeutics Market

• 26.1. Africa Liver Diseases Therapeutics Market Overview
• 26.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

• 27.1. Liver Diseases Therapeutics Market Competitive Landscape
• 27.2. Liver Diseases Therapeutics Market Company Profiles
  • 27.2.1. Astellas Pharma Inc
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Bristol-Myers Squibb Company
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. F Hoffmann-La Roche AG
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Merck & Co Inc
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Novartis AG
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market

29. Liver Diseases Therapeutics Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer